GLPGF OTC
Lakefront Biotherapeutics
1W: +0.0%
1M: +21.8%
3M: +13.8%
YTD: +2.1%
1Y: -4.5%
3Y: -19.1%
5Y: -72.8%
$31.95
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$1.1B
+303.4% ▲
5Y CAGR: +18.4%
Gross Profit
$1.1B
+349.4% ▲
Operating Income
$469M
+349.3% ▲
Net Income
$321M
+333.0% ▲
EPS (Diluted)
$4.87
+334.8% ▲
EBITDA
$469M
+983.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $485M | $505M | $240M | $276M | $1.1B |
| YoY Growth | +1.4% | +4.2% | -52.6% | +15.0% | +303.4% |
| Cost of Revenue | $2M | $12M | $36M | $35M | $30M |
| Gross Profit | $483M | $493M | $204M | $241M | $1.1B |
| Gross Margin | 99.7% | 97.6% | 85.0% | 87.4% | 97.3% |
| R&D Expenses | $492M | $515M | $241M | $335M | $459M |
| SG&A Expenses | $167M | $240M | $94M | $97M | $153M |
| Operating Expenses | $649M | $761M | $328M | $429M | $613M |
| Operating Income | -$166M | -$268M | -$88M | -$188M | $469M |
| Operating Margin | -34.2% | -52.9% | -36.8% | -68.3% | 42.2% |
| Interest Expense | $12M | $7M | $2M | $315K | $3M |
| Income Before Tax | -$123M | -$215M | $6M | -$3M | $301M |
| Tax Expense | $2M | $3M | $10M | -$2M | -$19M |
| Net Income | -$125M | -$218M | $212M | $74M | $321M |
| Net Margin | -25.9% | -43.1% | 88.3% | 26.9% | 28.9% |
| EPS (Diluted) | $-1.91 | $-3.32 | $3.21 | $1.12 | $4.87 |
| EBITDA | -$101M | -$33M | $43M | $43M | $469M |
| Shares Outstanding | 66M | 66M | 66M | 66M | 66M |